 HANOVER, MD, Oct. 12, 2021 GLOBE NEWSWIRE -- Processa Pharmaceuticals, Inc. NASDAQ: PCSA, Processa or the Company, a clinical-stage biopharmaceutical company developing products to improve the survival andor quality of life for patients who have unmet medical needs, announced today that they have been cleared by the U.S. Food and Drug Administration FDA to proceed with a Phase 2a clinical trial of PCS12852 in patients with moderate to severe gastroparesis, an unmet medical need condition for which patients need alternative, safer treatment options. 